Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia

J. Jankovic, C. Hunter, B. Z. Dolimbek, G. S. Dolimbek, C. H. Adler, A. Brashear, C. L. Comella, M. Gordon, D. E. Riley, Kapil Dev Sethi, C. Singer, M. Stacy, D. Tarsy, M. Z. Atassi

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.

Original languageEnglish (US)
Pages (from-to)2233-2235
Number of pages3
JournalNeurology
Volume67
Issue number12
DOIs
StatePublished - Dec 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Jankovic, J., Hunter, C., Dolimbek, B. Z., Dolimbek, G. S., Adler, C. H., Brashear, A., Comella, C. L., Gordon, M., Riley, D. E., Sethi, K. D., Singer, C., Stacy, M., Tarsy, D., & Atassi, M. Z. (2006). Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology, 67(12), 2233-2235. https://doi.org/10.1212/01.wnl.0000249308.66959.43